Beyond organ-specific therapies: A unified approach to multi-organ fibrosis

Basit Öğe Kaydı
dc.authorid0000-0001-8365-5712
dc.authorid0009-0005-1472-7563
dc.authorid0000-0002-8909-2102
dc.contributor.authorPan, Ziyan
dc.contributor.authorZerehpoosh, Shadi
dc.contributor.authorWang, Shu-Chi
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorKim, Won
dc.contributor.authorEslam, Mohammed
dc.date.accessioned2026-03-25T12:35:17Z
dc.date.available2026-03-25T12:35:17Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractOrgan fibrosis, characterized by excessive scarring of tissues in the liver, kidney, lung, and heart, poses a significant and growing global health challenge, resulting in considerable morbidity and mortality, with a lack of effective treatment options. Most research and drug development efforts have traditionally focused on individual organs in isolation. This review aims to provide a comprehensive perspective on multi-organ fibrosis, highlighting recent advances that clarify the complex cellular and molecular mechanisms involved in the liver, kidney, lung, and heart. It examines both common and organ-specific factors that drive fibrogenesis. Additionally, the review discusses the current and future landscape of antifibrotic therapies, including innovative approaches to developing pan-organ antifibrotic drugs. Challenges and future directions in the design of clinical trials are also addressed.
dc.description.sponsorshipZiyan Pan and Mohammed Eslam are supported by a National Health and Medical Research Council of Australia (NHMRC) investigator and ideas grants (AAP2008983 and APP2001692). Ziyan Pan ve Mohammed Eslam, Avustralya Ulusal Sağlık ve Tıbbi Araştırma Konseyi (NHMRC) araştırmacı ve fikir hibeleri (AAP2008983 ve APP2001692) tarafından desteklenmektedir.
dc.identifier.citationPan, Z., Zerehpoosh, S., Wang, S. C., Örmeci, N., Kim, W., Eslam, M. (2026). Beyond organ-specific therapies: A unified approach to multi-organ fibrosis. Drug Design, Development and Therapy, 20, pp. 1-14. https://doi.org/10.2147/DDDT.S566319
dc.identifier.doi10.2147/DDDT.S566319
dc.identifier.endpage14
dc.identifier.issn1177-8881
dc.identifier.pmidPMID: 4176926
dc.identifier.scopus2-s2.0-105030933285
dc.identifier.scopusqualityQ1
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.2147/DDDT.S566319
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1368
dc.identifier.volume20
dc.identifier.wosWOS:001699317200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.publisherDove Medical Press Ltd
dc.relation.ispartofDrug Design, Development and Therapy
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectFibrosis
dc.subjectAntifibrotic Therapy
dc.subjectMulti-Organ Disease
dc.subjectMyofibroblast
dc.subjectExtracellular Matrix
dc.subjectPrecision Medicine
dc.titleBeyond organ-specific therapies: A unified approach to multi-organ fibrosis
dc.typeReview Article
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text.pdf
Boyut:
4.03 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu